☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
App
Advertisement
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Report
Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III Trial for the Treatment of Eosinophilic Esophagitis
October 25, 2021
Merck and Ridgeback Report the Initiation of EMA Rolling Review of Molnupiravir for the Treatment of COVID-19
October 25, 2021
Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III Trial for the Treatment of Eosinophilic Esophagitis
October 25, 2021
Merck and Ridgeback Report the Initiation of EMA Rolling Review of Molnupiravir for the Treatment of COVID-19
October 25, 2021
Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III PRIME2 Trial for the Treatment of Prurigo Nodularis
October 22, 2021
Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III PRIME2 Trial for the Treatment of Prurigo Nodularis
October 22, 2021
Load more...
Back to Home